Questions:

1. Moderate hypofractionation is considered a standard of care in prostate radiotherapy. What is the state of the art in 2021 for extreme hypofractionation in prostate cancer?
2. What’s your point of view about the multidisciplinary approach to locally advanced prostate cancer?
3. Some very recent studies seems to close the neverending debate on adjuvant vs salvage radiotherapy. Could you summarize these findings?
4. Is there a role for local treatments in metastatic prostate cancer?
5. PSMA PET/CT is clearing changing the approach to prostate cancer. Could you summarize us how it can impact the therapeutic strategy for prostate cancer patients?